Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Biologics & Biosimilars Drug Updates adalimumab biosimilar substitution Enbrel etanercept Humira INFLECTRA (infliximabdyyb) REMICADE (infliximab) Rituxan rituximab Source Type: research